TRON Seminar in Translational Oncology: Prof. Stratton

November 24, 2011

5 PM in Mainz, Germany

TRON – Building 708 at University Medical Center Mainz

Langenbeckstr. 1

55131 Mainz

Prof. Mike Stratton

Wellcome Trust Sanger Institute, Cambridge, UK

“Evolution of the Cancer Genome”

Professor Stratton qualified in medicine, trained as a histopathologist, and was inspired by the understanding of disease processes that can be revealed by microscopy. During his training, he recognised the opportunities to understand causes of cancer through molecular biology and genetics. Since 2010 he has been the Director of the Sanger Institute. He leads the highly successful Cancer Genome Project and is a leader of the International Cancer Genome Consortium.

Professor Stratton’s interests are in the genetics of cancer. His early work focused on genes that increase susceptibility to cancer, such as BRCA2, a gene that, when mutated, greatly increases a woman’s risk of breast cancer. His team at the Sanger Institute studies the pathology of cancer genomes, conducting high-throughput, genome-wide searches for acquired, rather than inherited, mutations in human cancer in order to identify new cancer genes, to understand processes of mutation in human cancers and to reveal the role of genome structure in determining abnormalities of cancer genomes. In these studies Mike’s team discovered mutations in the BRAF and ERBB2 genes in melanoma and lung cancer, respectively, and have described the patterns of acquired mutation in human cancer genomes.

Under his direction, the Sanger Institute is conducting large scale analyses of genomes and experimental studies in model organisms to develop cellular systems that will explore human biology and provide transformative insights into how diseases develop.

For more information contact ed.zn1495494460iam-n1495494460ort@e1495494460ciffo1495494460-tnor1495494460f1495494460

( Click here for more information on Mike Stratton )